Rhodanine derivatives as selective protease inhibitors against bacterial toxins
- PMID: 18221310
- DOI: 10.1111/j.1747-0285.2007.00617.x
Rhodanine derivatives as selective protease inhibitors against bacterial toxins
Abstract
In this study, we analyzed a series of rhodanine derivatives, as potential inhibitors of bacterial toxins, namely the proteases anthrax lethal factor and the botulinum neurotoxin type A. Conducting an extensive structure-activity relationship study on rhodanine derivatives, we profiled their selectivity against the two bacterial toxins and two related human metalloproteases using in vitro assays. In addition, we examined initial in vitro ADME-Tox properties of selected compounds and their ability to protect lethal factor-induced cell death of macrophages. These data allowed the selection of one additional drug candidate for which preliminary in vivo efficacy studies against anthrax spores were conducted. Integration of these results with our structure-activity relationship studies provides a framework for the development of potential drug candidates against anthrax and botulinum.
Similar articles
-
Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors.Bioorg Med Chem Lett. 2006 Mar 15;16(6):1527-31. doi: 10.1016/j.bmcl.2005.12.038. Epub 2006 Jan 4. Bioorg Med Chem Lett. 2006. PMID: 16386899
-
Combating the threat of anthrax: a quantitative structure-activity relationship approach.Mol Pharm. 2008 Sep-Oct;5(5):745-59. doi: 10.1021/mp8000149. Epub 2008 Jul 9. Mol Pharm. 2008. PMID: 18611038
-
Beta-cyclodextrin derivatives that inhibit anthrax lethal toxin.Bioorg Med Chem. 2006 Jan 1;14(1):33-40. doi: 10.1016/j.bmc.2005.07.054. Epub 2005 Sep 19. Bioorg Med Chem. 2006. PMID: 16169738
-
Polyvalency: a promising strategy for drug design.Biotechnol Bioeng. 2008 Oct 15;101(3):429-34. doi: 10.1002/bit.22056. Biotechnol Bioeng. 2008. PMID: 18727104 Review.
-
Dysport: pharmacological properties and factors that influence toxin action.Toxicon. 2009 Oct;54(5):683-9. doi: 10.1016/j.toxicon.2009.03.020. Epub 2009 Mar 28. Toxicon. 2009. PMID: 19332087 Review.
Cited by
-
New 5-ylidene rhodanine derivatives based on the dispacamide A model.Mol Divers. 2014 May;18(2):375-88. doi: 10.1007/s11030-014-9509-7. Epub 2014 Mar 2. Mol Divers. 2014. PMID: 24584455
-
Identification of novel non-hydroxamate anthrax toxin lethal factor inhibitors by topomeric searching, docking and scoring, and in vitro screening.J Chem Inf Model. 2009 Dec;49(12):2726-34. doi: 10.1021/ci900186w. J Chem Inf Model. 2009. PMID: 19928768 Free PMC article.
-
Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone Pharmacophore.Open Access Bioinformatics. 2010 Apr 1;2010(2):11-18. doi: 10.2147/OAB.S7251. Open Access Bioinformatics. 2010. PMID: 21103387 Free PMC article.
-
Development of a comprehensive, validated pharmacophore hypothesis for anthrax toxin lethal factor (LF) inhibitors using genetic algorithms, Pareto scoring, and structural biology.J Chem Inf Model. 2012 Jul 23;52(7):1886-97. doi: 10.1021/ci300121p. Epub 2012 Jun 25. J Chem Inf Model. 2012. PMID: 22697455 Free PMC article.
-
Small molecules showing significant protection of mice against botulinum neurotoxin serotype A.PLoS One. 2010 Apr 13;5(4):e10129. doi: 10.1371/journal.pone.0010129. PLoS One. 2010. PMID: 20405003 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information